Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock
Key stats
- Market cap
- $92.52M
- Price / Earnings ratio
- -2.2x
- EPS (TTM)
- -$0.75
- Volume
- Loading
- 52-week high
- $4.94
- 52-week low
- $1.58
Source: third-party data provider, as of November 13, 2026
Compare with BDTX
Recent news

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
BDTX

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
BDTX

Black Diamond Stock Outlook After Q1 Beat and Cash Runway
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
BDTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 41.75
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.04
- MACD histogram
- -0.02
- SMA 50
- $1.88
- Price below SMA 50
- EMA 50
- $1.86
- Price below EMA 50
- SMA 200
- $2.16
- Price below SMA 200
- EMA 200
- $2.21
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
BDTX

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
BDTX

Black Diamond Stock Outlook After Q1 Beat and Cash Runway
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
BDTX

BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
BDTX

Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
BDTX

BDTX Shares Gain 11% in a Week: Here's What You Should Know
BDTX Shares Gain 11% in a Week: Here's What You Should Know
BDTX

Implied Volatility Surging for Black Diamond Therapeutics Stock Options
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
BDTX

BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
BDTX

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
BDTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Black Diamond Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark A. Velleca M.D., Ph.D. | CEO, President & Chairman | 1964 |
| Mr. Brent Hatzis-Schoch Esq., J.D. | COO & General Counsel | 1965 |
| Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer | 1969 |
| Dr. Elizabeth Buck Ph.D. | Co-Founder & Chief Scientific Officer | 1975 |
| Ms. Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller | 1985 |
| Ms. Melanie Morrison | Chief Development Officer | 1975 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 41.75
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.04
- MACD histogram
- -0.02
- SMA 50
- $1.88
- Price below SMA 50
- EMA 50
- $1.86
- Price below EMA 50
- SMA 200
- $2.16
- Price below SMA 200
- EMA 200
- $2.21
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $11.00
- Average
- $11.00
- High
- $11.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -21.6 | -9.5 | ||||||||||
| 2022 | -25.7 | -27.6 | -8.9 | -11.6 | -28.4 | +45.6 | +33.6 | -7.3 | -46.0 | +35.9 | -10.2 | -12.6 |
| 2023 | +63.0 | -40.8 | +0.0 | -25.9 | +17.0 | +134.9 | -20.5 | -8.9 | -19.4 | -32.4 | +26.5 | +19.1 |
| 2024 | +32.0 | +20.9 | +6.1 | +13.0 | -19.0 | -1.5 | +29.6 | +0.7 | -24.6 | -34.3 | -8.3 | -17.4 |
| 2025 | +22.4 | -18.0 | -18.8 | +14.1 | +29.4 | +4.6 | +7.3 | +6.2 | +35.4 | +4.0 | -3.3 | -35.5 |
| 2026 | +0.0 | -2.8 | -12.3 | +13.7 | -14.6 | -18.1 | -8.2 | +20.7 | -7.4 | -5.3 | -8.0 |



